Following the observation that metastatic melanoma patients with high levels of VEGF presented worse survival when treated with ipilimumab, a CTLA4 inhibitor [199], a phase I trial was conducted to investigate the combination of ipilimumab with bevacizumab. This evidence concerns the gene VEGFA and metastatic melanoma.